Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03643744 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy-Induced Immune Modulation: Part III
A Phase 1 study, sponsored by Wright State University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03643744 is a Phase 1 study that was terminated before completion, run by Wright State University. The registered enrollment target is 12 participants.
The verdict
NCT03643744, a Phase 1 study, was terminated before completion, sponsored by Wright State University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is designed as a double-blinded proof of concept of feasibility study to define if the immunosuppression associated with photodynamic therapy (PDT) can be blocked by treatment with cyclo-oxygenase-2 (COX-2) inhibitor celecoxib in comparison to placebo. PDT consists of application of the photosensitizer 5-aminolevulinic acid followed by treatment with a blue light. PDT is used to treat pre-cancerous actinic keratosis on large areas of skin. These studies are a continuation of ongoing studies that indicate that the lipid mediator platelet-activating factor (PAF) is generated in skin following PDT, and that PDT suppresses the immune system. It is hypothesized that PDT-generated PAF results in the immunosuppression associated with PDT. Therefore, it is proposed that a treatment to block that immunosuppression could protect the patient undergoing PDT. Blockers of the PAF system are not currently commercially available. However research studies done at Wright State University using mice indicate that PAF- and PDT-induced immunosuppression is blocked by treatment with COX-2 inhibitors. This study is conducted as a proof of concept. Study length and visit for subjects with actinic keratoses: The first part of the study is completed in 12 days then there are follow up visits at 6 and 12 months. There are a total of 6 separate visits to the research office. Study length and visit for control subjects: The study is completed in 10 days. There are a total of 4 separate visits to the research office.
Interventions
- DRUG Placebo
- DRUG Celecoxib 200mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2023-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03643744
The ClinicalTrials.gov registry entry for NCT03643744 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wright State University, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03643744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03643744 about?
NCT03643744 is a clinical study titled "Photodynamic Therapy-Induced Immune Modulation: Part III". This study is designed as a double-blinded proof of concept of feasibility study to define if the immunosuppression associated with photodynamic therapy (PDT) can be blocked by treatment with cyclo-oxygenase-2 (COX-2) inhibitor celecoxib in comparison to placebo. PDT consists of application of the p...
What is the current status of trial NCT03643744?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-04-01. Estimated completion is 2023-03-21.
What interventions are being tested in trial NCT03643744?
The interventions under investigation include: Placebo (DRUG), Celecoxib 200mg (DRUG).
Who is sponsoring clinical trial NCT03643744?
This trial is sponsored by Wright State University, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.